The group's principal activity is to conduct research and development of therapeutics for the treatment of certain life-threatening antibody-mediated diseases. The diseases include autoimmune conditions such as systemic lupus erythematosus and antibody-mediated stroke that are caused by abnormal b cell production of antibodies that attach healthy tissues. The current therapies for these autoimmune disorders target the symptoms of the diseases or nonspecifically suppress the normal operation of the immune system. The group's strategy is to collaborate with pharmaceutical companies to access their research, drug development, manufacturing, marketing and financial resources.
